PAIYY 20-F SEC Filing Analysis

Latest settled — T+20d

PAIYY ▼ -84.04% at T+20d

SHORT call ✓ call won +84.04% · α vs SPY +88.07% · entry $0.0940 → $0.0150

Next anchor: T+60d in 5w

Currently $0.0150 · +84.04% from $0.0940 entry (call sign-flipped)

Entry anchored
Apr 23, 2026
via day open

T+1d

0.00%

call 0.00% · α +0.16%

$0.0940

settled 7w ago

T+5d

-44.68%

call +44.68% · α +45.59%

$0.0520

settled 6w ago

T+20d

-84.04%

call +84.04% · α +88.07%

$0.0150

settled 23d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Aesthetic Medical International Holdings Group Ltd (PAIYY) reported a net loss of $7.7 million in 2025, a significant deterioration from a $25.1 million loss in 2024, driven by a 4.3% revenue decline. The company continues to face challenges with its OTC listing and potential delisting under the HFCAA if PCAOB inspections are not maintained. Despite these headwinds, the company is strategically shifting focus toward higher-margin surgical services and has strengthened its corporate governance.

Actionable Insight

Monitor the company's OTCQX compliance status closely, as a failure to regain the minimum bid price could lead to further downgrades. The company's ability to maintain its auditor's PCAOB inspection status is critical to avoid delisting under the HFCAA. The strategic shift to higher-margin surgical services is a positive, but its success should be evaluated against the backdrop of declining overall revenue.

Key Facts

Net loss for 2025 was $54.1 million (RMB388.6 million), a 115% increase from the $25.1 million loss in 2024.
Total revenue decreased by 4.3% to $103.4 million (RMB722.9 million) in 2025, down from $107.9 million (RMB755.7 million) in 2024.
The company is currently listed on the OTCQX Best Market after being delisted from Nasdaq in July 2024 and received a notice in February 2026 for failing to meet the minimum bid price requirement.
The company is subject to the Holding Foreign Companies Accountable Act (HFCAA) and could face delisting if the PCAOB is unable to inspect its auditor, Onestop Assurance PAC, for two consecutive years.
The company's gross margin improved to 46.2% in 2025 from 44.7% in 2024, driven by a strategic shift towards higher-margin surgical aesthetic services.

Financial Impact

The company reported a net loss of $54.1 million in 2025, a significant increase from the $25.1 million loss in 2024. Total revenue decreased by 4.3% to $103.4 million.

revenueepsgross_margin

Risk Factors

Delisting risk due to non-compliance with OTCQX bid price requirements and the HFCAA.
Continued decline in revenue and profitability.
Reliance on a complex corporate structure with associated risks.

Market Snapshot

Exchange

OTC

Sector

Services-Specialty Outpatient Facilities, NEC

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 11 SEC documents filed with EDGAR.

Document	Accession Number
20-F Filing (Primary)	0001185185-26-001477
Document: paiyyex12-2.htm	0001185185-26-001477
Document: paiyyex12-1.htm	0001185185-26-001477
Document: paiyyex8-1.htm	0001185185-26-001477
Document: paiyyex13-1.htm	0001185185-26-001477
Document: paiyyex13-2.htm	0001185185-26-001477
Document: paiyyex15-1.htm	0001185185-26-001477
Document: paiyyex15-2.htm	0001185185-26-001477
Document: 0001185185-26-001477-index-headers.html	0001185185-26-001477
Document: 0001185185-26-001477-index.html	0001185185-26-001477
Document: 0001185185-26-001477.txt	0001185185-26-001477

US Market Status

Market Closed — Opens Mon (49h 28m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access